This article can be found at http://www.theguardian.com/society/2015/jul/25/alzheimers-drugs-eli-lilly-solanezumab-david-mann Major improvements must be made in techniques for identifying future Alzheimer's disease patients if medicine is to take advantage of drugs that could inhibit or halt their mental decline. This warning was made last week by several senior scientists after the announcement by the pharmaceutical giant Eli Lilly that its drug, solanezumab, had Continue Reading
